AGILE SCIENCES, INC.
RALEIGH, NC, 27606-5243
DUNS: 828576202
# of Employees: 3
HUBZone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Award Charts
Award Listing
-
Record 1 TO 15
-
Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria
Amount: $294,309.00DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives ...
STTRPhase I2016Department of Health and Human Services -
Development of novel anti-biofilm compounds for treating chronic wounds
Amount: $1,467,974.00DESCRIPTION provided by applicant Chronic wounds that fail to respond to traditional therapeutic interventions afflict millions of people each year and direct costs associated with treating these ...
SBIRPhase II2015Department of Health and Human Services -
Small molecules as antibiotic potentiating agents against multi-drug resistant Gram-negative infections
Amount: $1,237,602.00DESCRIPTION provided by applicant Antibiotic resistance has been declared one of the three greatest threats to human health by the World Health Organization Infections caused by multi drug resista ...
SBIRPhase II2015Department of Health and Human Services -
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
Amount: $1,499,094.00DESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these in ...
STTRPhase II2014Department of Health and Human Services National Institutes of Health -
Evaluation of a new class of molecules for treating MRSA infective endocarditis
Amount: $300,000.00DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for en ...
STTRPhase I2013Department of Health and Human Services -
Targeting Oral Biofilms with 2-Aminoimidazole/Triazole Conjugates
Amount: $1,030,274.00DESCRIPTION (provided by applicant): Dental caries is one of the most prevalent diseases in the U.S. with 85% of adults and the majority of children having been treated for at least one incidence. Wh ...
SBIRPhase II2012Department of Health and Human Services -
SBIR Phase I: Enhancing the Bactericidal Activity of Copper: An Economically Viable Solution for Lowering Copper Usage Rates in Agriculture
Amount: $150,000.00This Small Business Innovation Research Phase I project describes a cost-effective method for reducing the quantities of copper used for agricultural crop protection. Currently, millions of pounds of ...
SBIRPhase I2012National Science Foundation -
Small Molecules to Enhance Bacterial Susceptibility to Antiseptics
Amount: $257,221.00DESCRIPTION (provided by applicant): One-third of costs associated with hospital acquired infections (HAIs) are attributed to surgical site infections (SSIs), and SSIs result in a two-fold increase in ...
SBIRPhase I2012Department of Health and Human Services -
SBIR Phase I: Preventing Biofilms on Indwelling Medical Devices with Novel Anti-Biofilm Small Molecules
Amount: $150,000.00This Small Business Innovation Research (SBIR) Phase I project describes a new approach for reducing infections associated with indwelling medical devices. Bacteria on medical devices are particularly ...
SBIRPhase I2011National Science Foundation -
Development of Small Molecules to Combat Bacterial Biofilms
Amount: $545,129.00DESCRIPTION (provided by applicant): Bacterial infections are responsible for an estimated 100,000 deaths in the United States each year, and despite the dire unmet medical need, few new treatment op ...
SBIRPhase I2011Department of Health and Human Services
